Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.

Fulminant hepatic failure (FHF) is a serious clinical condition that is associated with high mortality. There is evidence that FHF is an inflammatory disease, which is supported clinically by elevated serum levels of cytokines. In an effort to develop hepatocytes with additional functions for use in our bioartificial liver (BAL) device, we focused on interleukin-1 (IL-1) blockade as a therapeutic modality. Primary porcine hepatocytes were isolated from the livers of miniature swine and then transfected with an adenoviral vector encoding human interleukin-1 receptor antagonist (AdIL-1Ra). The transfected hepatocytes secreted human IL-1Ra. These transfected hepatocytes were incorporated into a flat-plate BAL device to evaluate their efficacy in treating D-galactosamine (GalN)- induced FHF in a rat model. After extracorporeal perfusion with the BAL device containing the transfected hepatocytes, there were significant reductions in the plasma levels of hepatic enzymes (aspartate aminotransferase and alanine aminotransferase) and cytokines (IL-1 and IL-6), indicating a beneficial effect. Animal survival was significantly improved in the treated group compared to the control group. These experiments demonstrate that combining inflammatory cytokine blockade with a functional BAL device may be an effective therapeutic option in the treatment of FHF.

[1]  E. Mylona,et al.  Acute hepatitis in adult Still’s disease during corticosteroid treatment successfully treated with anakinra , 2008, Clinical Rheumatology.

[2]  Henrik Pedersen,et al.  Control of hepatic differentiation via cellular aggregation in an alginate microenvironment , 2007, Biotechnology and bioengineering.

[3]  J. Fishman,et al.  Xenotransplantation: Infectious Risk Revisited , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  Mehmet Toner,et al.  A Fulminant Hepatic Failure Model in the Rat , 2001, Digestive Diseases and Sciences.

[5]  Mehmet Toner,et al.  Efficacy of an extracorporeal flat-plate bioartificial liver in treating fulminant hepatic failure. , 2003, The Journal of surgical research.

[6]  M. Kitajima,et al.  Transfer Of The Interleukin-1 Receptor Antagonist Gene Into Rat Liver Abrogates Hepatic Ischemia-Reperfusion Injury , 2002, Transplantation.

[7]  E. Galun,et al.  The role of cytokines in liver failure and regeneration: potential new molecular therapies. , 2002, Biochimica et biophysica acta.

[8]  T. Tanimoto,et al.  Serum gamma‐interferon‐inducing factor (IL‐18) and IL‐10 levels in patients with acute hepatitis and fulminant hepatic failure , 2002, Journal of gastroenterology and hepatology.

[9]  M L Yarmush,et al.  In vitro and in vivo evaluation of albumin synthesis rate of porcine hepatocytes in a flat-plate bioreactor. , 2001, Artificial organs.

[10]  X. M. Fernández-Suárez,et al.  Analysis of patients treated with living pig tissue for evidence of infection by porcine endogenous retroviruses. , 2001, Trends in cardiovascular medicine.

[11]  W. Heneine,et al.  Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia. , 2001, The Journal of infectious diseases.

[12]  M L Yarmush,et al.  A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha. , 2001, Digestive diseases and sciences.

[13]  S. Bhatia,et al.  Xenobiotic metabolism by cultured primary porcine hepatocytes. , 2000, Tissue engineering.

[14]  C. Dinarello.  The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. , 2000, The New England journal of medicine.

[15]  NB Beck,et al.  Baculovirus vectors repress phenobarbital-mediated gene induction and stimulate cytokine expression in primary cultures of rat hepatocytes , 2000, Gene Therapy.

[16]  Y. Takeuchi,et al.  Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV) , 2000, Xenotransplantation.

[17]  M. Toner,et al.  In Vitro Characterization of Porcine Hepatocyte Function , 2000, Cell transplantation.

[18]  L. Corcos,et al.  Detoxifying activity in pig livers and hepatocytes intended for xenotherapy. , 1999, Transplantation.

[19]  M. Murai,et al.  Overexpression of IL-1ra gene up-regulates interleukin-1β converting enzyme (ICE) gene expression: possible mechanism underlying IL-1β-resistance of cancer cells , 1999, British Journal of Cancer.

[20]  R. Weiss,et al.  Host range and interference studies of three classes of pig endogenous retrovirus. , 1999, Journal of virology.

[21]  R. Weiss,et al.  No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys , 1998, The Lancet.

[22]  R. Weiss,et al.  Two sets of human-tropic pig retrovirus , 1997, Nature.

[23]  Yasuhiro Takeuchi,et al.  Infection of human cells by an endogenous retrovirus of pigs , 1997, Nature Medicine.

[24]  M. Kitajima,et al.  Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. , 1997, Transplantation.

[25]  Y. Kanegae,et al.  Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Samuel,et al.  Orthotopic Liver Transplantation in Fulminant and Subfulminant Hepatitis The Paul Brousse Experience , 1995, Annals of surgery.

[27]  B. Reitz,et al.  Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. , 1995, Journal of pharmaceutical sciences.

[28]  A. Thomson,et al.  Circulating proinflammatory cytokines (IL‐1β, TNF‐α, and IL‐6) and IL‐1 receptor antagonist (IL‐1Ra) in fulminant hepatic failure and acute hepatitis , 1994 .

[29]  R. Hughes,et al.  Extent of the acute phase response in fulminant hepatic failure. , 1994, Gut.

[30]  A. Thomson,et al.  Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. , 1994, Clinical and experimental immunology.

[31]  C. Dinarello,et al.  Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. , 1992, Blood.

[32]  R. Tompkins,et al.  Long‐Term in Vitro Function of Adult Hepatocytes in a Collagen Sandwich Configuration , 1991, Biotechnology progress.

[33]  C. J. Dunn,et al.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein , 1990, Nature.

[34]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[35]  T. Ishizuya,et al.  In-vitro preparation of experimental models of hepatitis with D-galactosamine and their modification by liver-repairing factors. , 1990, International journal of tissue reactions.

[36]  R. Tompkins,et al.  Hepatocyte function and extracellular matrix geometry: long‐term culture in a sandwich configuration , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  D. Samuel,et al.  Liver transplantation in fulminant and subfulminant hepatitis , 1989 .

[38]  K. Nouri-Aria,et al.  ENHANCED TUMOUR NECROSIS FACTOR AND INTERLEUKIN-1 IN FULMINANT HEPATIC FAILURE , 1988, The Lancet.